|Bid||70.20 x 800|
|Ask||70.22 x 1400|
|Day's range||69.56 - 70.45|
|52-week range||48.78 - 70.76|
|Beta (3Y monthly)||1.08|
|PE ratio (TTM)||36.56|
|Earnings date||31 Jul 2019 - 5 Aug 2019|
|Forward dividend & yield||N/A (N/A)|
|1y target est||69.94|
Doctors’ offices and hospitals have switched en masse from paper to digital records over the past decade. For investors, the first era of electronic records proved lucrative as the government pumped tens of billions of dollars into the industry. Most hospitals and doctors’ offices already have systems in place, and taxpayer support is drying up.
Cerner is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
On April 25, MNG Enterprises reported in a filing that it held a stake of 8,506,799 shares in the news media publisher, equal to 7.5% of the tradable stock. MNG also revealed in the filing that it had halved the number of nominees for election to Gannett’s board at the upcoming annual shareholders meeting. Within this latest filing, ADW also listed a number of actions it has taken to spur the home retailer into exploring strategic alternatives for the firm.
The big healthcare-technology provider hit its first-quarter guidance thanks to solid professional services and managed services revenue growth.
On a per-share basis, the North Kansas City, Missouri-based company said it had profit of 51 cents. Earnings, adjusted for one-time gains and costs, came to 61 cents per share. The results met Wall Street ...
In this article we are going to estimate the intrinsic value of Cerner Corporation (NASDAQ:CERN) by taking the foreast future cash flows of the company and discounting them back to today's value. I will use the Discounted Cash...
Zacks.com featured expert Kevin Matras highlights: Ralph Lauren, Cerner, KeyW, Fifth Third and Energy Transfer
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Top-line growth and solid show by Population Health, Revenue Cycle and IT Works are likely to aid Cerner (CERN) in Q1. However, expected decline in bookings is likely to be a dampener.
Brokers have a deeper understanding of stocks, industries and the overall economy. Thus, it is wise to follow their advice to ensure robust returns.
Cerner (CERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Shares of Cerner are up 20% this year but the medical records company can still rise much further as it is still cheap, activist investor Jeff Smith said Tuesday.
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Cerner (CERN) and naviHealth coordinate to provide EHR offering that is expected to benefit health care providers in the form of affordable and accessible health care centered on the patient.
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.